tirzepatide and type 1 diabetes Groundbreaking Trial Testing for Changes in Basal and Bolus

Studies of orforglipron (Foundayo) showed significant and sustained weight loss (at least 10% of starting weight) over 72 weeks

Any practice that plans to offer or is currently offering the compounded drugs should keep in mind that they may need to switch how and from where it obtains the medication at some point in the future

It is of utmost importance to tailor treatment based on a patients genes, environment and previous medication use to improve overall outcomes, decrease patients exposure to a drug that might not be effective and be considerate of the financial burden that patients may endure, Andres J

12,15 GLP-1 RAs have been licenced (at higher doses than those used for diabetes) for the treatment of obesity